-
Paratek Pharmaceuticals (PRTK) to Acquire OptiNose (OPTN)
-
Paratek Pharmaceuticals to Acquire Optinose
-
OptiNose (OPTN) Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
-
Optinose (OPTN) PT Raised to $18 at H.C. Wainwright
-
OptiNose (OPTN) Announces 1:15 Reverse Share Split
-
Optinose (OPTN) PT Lowered to $1 at Piper Sandler
-
OptiNose (OPTN) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
-
OptiNose (OPTN) Appoints Terry Kohler as CFO
-
OptiNose (OPTN) Tops Q2 EPS by 1c ; Offers Guidance

